NCT03568539View on ClinicalTrials.gov

IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 27, 2018

Primary Completion Date

November 9, 2020

Study Completion Date

December 7, 2020

Conditions
Advanced/Metastatic Solid Malignancies
Interventions
DRUG

IBI308

IBI308 200mg IV infusion, every 3 weeks.

Trial Locations (7)

10029

Icahn School of Medicine at Mount Sinai, New York

30342

Northside Hospital, Inc, Atlanta

48202

Henry Ford Medical Center, Detroit

73104

University of Oklahoma Health Sciences Center, Oklahoma City

75230

Mary Crowley Cancer Research, Dallas

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

92868

UC Irvine Medical Center, Orange

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT03568539 - IBI308 in Subjects With Advanced/Metastatic Solid Malignancies | Biotech Hunter | Biotech Hunter